Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

23.76 +1.18 (+5.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at Jefferies Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Inc. (NASDAQ: CLDX) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.